Tags

Type your tag names separated by a space and hit enter

Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients.
Phytomedicine 2003; 10 Suppl 4:38-49P

Abstract

OBJECTIVE

An 8-week randomized, reference-controlled, double-blind, multi-centre clinical trial investigated Kava-Kava LI 150 in Generalized Anxiety Disorder (GAD; ICD-10: F41.1).

METHOD

129 out-patients received either 400 mg Kava LI 150, 10 mg Buspirone or 100 mg Opipramol daily for 8 weeks. At week 9, subjects were seen to check for symptoms of withdrawal or relapse. Primary outcome measures comprised the HAMA scale and the proportion of responders at week 8. Secondary measures were the Boerner Anxiety Scale (BOEAS), SAS, CGI, a self-rating scale for well-being (Bf-S), a sleep questionnaire (SF-B), a quality-of-life questionnaire (AL) and global judgements by investigator and patients.

RESULTS

In 127 patients (ITT) no significant differences could be observed regarding all efficacy and safety measures. About 75% of patients were classified as responders (50% reduction of HAMA score) in each treatment group, about 60% achieved full remission.

CONCLUSION

Kava-Kava LI150 is well tolerated and as effective as Buspirone and Opipramol in the acute treatment of out-patients suffering from GAD.

Authors+Show Affiliations

Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany. reinhard.boerner@psy.med.uni-muenchen.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12807341

Citation

Boerner, R J., et al. "Kava-Kava Extract LI 150 Is as Effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-week Randomized, Double-blind Multi-centre Clinical Trial in 129 Out-patients." Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, vol. 10 Suppl 4, 2003, pp. 38-49.
Boerner RJ, Sommer H, Berger W, et al. Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine. 2003;10 Suppl 4:38-49.
Boerner, R. J., Sommer, H., Berger, W., Kuhn, U., Schmidt, U., & Mannel, M. (2003). Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, 10 Suppl 4, pp. 38-49.
Boerner RJ, et al. Kava-Kava Extract LI 150 Is as Effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-week Randomized, Double-blind Multi-centre Clinical Trial in 129 Out-patients. Phytomedicine. 2003;10 Suppl 4:38-49. PubMed PMID: 12807341.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. AU - Boerner,R J, AU - Sommer,H, AU - Berger,W, AU - Kuhn,U, AU - Schmidt,U, AU - Mannel,M, PY - 2003/6/17/pubmed PY - 2003/8/15/medline PY - 2003/6/17/entrez SP - 38 EP - 49 JF - Phytomedicine : international journal of phytotherapy and phytopharmacology JO - Phytomedicine VL - 10 Suppl 4 N2 - OBJECTIVE: An 8-week randomized, reference-controlled, double-blind, multi-centre clinical trial investigated Kava-Kava LI 150 in Generalized Anxiety Disorder (GAD; ICD-10: F41.1). METHOD: 129 out-patients received either 400 mg Kava LI 150, 10 mg Buspirone or 100 mg Opipramol daily for 8 weeks. At week 9, subjects were seen to check for symptoms of withdrawal or relapse. Primary outcome measures comprised the HAMA scale and the proportion of responders at week 8. Secondary measures were the Boerner Anxiety Scale (BOEAS), SAS, CGI, a self-rating scale for well-being (Bf-S), a sleep questionnaire (SF-B), a quality-of-life questionnaire (AL) and global judgements by investigator and patients. RESULTS: In 127 patients (ITT) no significant differences could be observed regarding all efficacy and safety measures. About 75% of patients were classified as responders (50% reduction of HAMA score) in each treatment group, about 60% achieved full remission. CONCLUSION: Kava-Kava LI150 is well tolerated and as effective as Buspirone and Opipramol in the acute treatment of out-patients suffering from GAD. SN - 0944-7113 UR - https://www.unboundmedicine.com/medline/citation/12807341/Kava_Kava_extract_LI_150_is_as_effective_as_Opipramol_and_Buspirone_in_Generalised_Anxiety_Disorder__an_8_week_randomized_double_blind_multi_centre_clinical_trial_in_129_out_patients_ L2 - http://www.diseaseinfosearch.org/result/7698 DB - PRIME DP - Unbound Medicine ER -